Following the CHMP’s positive opinion, the European Commission will render an official decision as to the authorization of the use of TAVNEOS in the European Union in January 2022.

U.S. IXPLORE Phase II trial achieved its objective; vilobelimab was shown to be safe and well tolerated in patients with ANCA-associated vasculitis when added to current standard of careEU ...